Contribution of Connexin Hemichannels to the Pathogenesis of Acute Lung Injury

Area of Science:

• Cellular Biology
• Molecular Medicine
• Pulmonary Research

Background:

• Connexin (Cx) proteins form hemichannels (HCs) and gap junctions (GJs), but HC functions remain unclear due to lack of selective targeting agents.
• Acute lung injury (ALI) is a severe condition with limited therapeutic options, and the role of Cx HCs in its pathogenesis is not fully understood.

Purpose of the Study:

• To characterize the broad-spectrum hemichannel blocking properties of a novel peptide mimetic (P5).
• To investigate the role of connexin hemichannels in acute lung injury (ALI) and their potential as therapeutic targets.

Main Methods:

• Administration of P5 peptide to various cell types (pulmonary microvascular endothelial cells, HepG2, astrocytes) and in vivo ALI models.
• Assessment of hemichannel permeability, high mobility group box protein 1 (HMGB1) release, leukocyte accumulation, and mortality in ALI mouse models.
• Biochemical analysis of bronchoalveolar lavage fluid (BALF) for liver enzymes (ALT, AST, LDH) and cell counts.

Main Results:

• P5 demonstrated broad-spectrum blockade of connexin hemichannel permeability across different cell types and in vivo.
• P5 significantly reduced HMGB1 release from vascular endothelial cells and its accumulation in BALF during endotoxin-induced ALI.
• P5 administration attenuated ALI-associated inflammation, including decreased leukocyte infiltration (neutrophils and monocytes), reduced liver enzyme levels in BALF, and lowered mortality rates.

Conclusions:

• Connexin hemichannels play a critical role in mediating HMGB1 release and augmenting leukocyte recruitment in acute lung injury.
• The P5 peptide is a potent and broad-spectrum connexin hemichannel blocker with therapeutic potential for treating ALI.
• Targeting connexin hemichannels represents a promising strategy for mitigating the pathology and mortality associated with acute lung injury.